Recent Updates
Recently added Catalysts
HLN Positive Sentiment

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Key Takeaway: Haleon has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney, who previously worked at Estée Lauder and P&G, replaces Franck Riot, who is leaving after six years. CEO Brian McNamara expressed confidence in Haney's ability to drive innovation and contribute to Haleon's growth strategy.
Price reaction · baseline $10.49 (2025-06-23 close) · hit pre-market · clean, no other HLN news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Carl Haney brings extensive experience in R&D from Estée Lauder and P&G.
  • Haleon aims to capitalize on significant opportunities with new leadership.
  • The appointment is seen as a strategic move to enhance innovation.

Full Press Release Details

LONDON,June 24, 2025/PRNewswire/ -- Haleon (LSE: HLN) (NYSE:HLN) today announces the appointment ofCarl Haneyas Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.
This appointment follows Franck Riot deciding to leave Haleon after six years in the business.
Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.

Brian McNamara, Haleon's Chief Executive Officer commented:

"I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon's significant potential through our new Win as One strategy.
"I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future."

Carl Haneycommented:

"I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon's ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August."

About Haleon

Haleon (LSE/NYSE:HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such asAdvil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, TherafluandVoltaren- are built on trusted science, innovation and deep human understanding.

Frequently Asked Questions

Who is the new Chief R&D Officer of Haleon?

Carl Haney has been appointed as Haleon's Chief R&D Officer.

When will Carl Haney start at Haleon?

Carl Haney will join Haleon on August 1, 2025.

Who did Carl Haney replace at Haleon?

Carl Haney replaces Franck Riot, who is leaving after six years.

What is Haleon's focus in consumer health?

Haleon aims to deliver better everyday health with humanity.

Last updated: Jun 24, 2025